Folate-Targeted Liposomes for Inflammatory Tissue Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory diseases, such as arthritis and atherosclerosis, face challenges in delivering therapeutic agents specifically to inflamed tissues while minimizing uptake by the mononuclear phagocyte system and plasma components, leading to reduced efficacy and increased side effects.
Innovation Solution
Development of folate-receptor targeted liposomal compositions and dendrimer conjugates that incorporate anti-inflammatory agents and imaging agents, utilizing a folate-targeting ligand to selectively deliver therapeutic and diagnostic agents to inflamed tissues by exploiting the high expression of folate receptors on activated macrophages and endothelial cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional liposomal compositions are used to deliver therapeutic agents, then systemic distribution occurs, but specific delivery to inflamed tissues is reduced
Solution Approach 1:
The liposomal composition incorporates a targeting ligand that binds specifically to receptors overexpressed on activated macrophages and endothelial cells at inflamed sites. This creates local specificity by enabling the liposome to recognize and bind to target cells only in the inflamed region, while maintaining different properties (targeting capability) only where needed rather than throughout the entire system
Solution Approach 2:
The invention modifies the surface properties of the liposome by attaching a targeting ligand, changing its biological recognition parameters. This allows the liposome to transition from non-specific systemic circulation to specific binding at inflamed tissues by altering its surface characteristics to match the receptor profile of activated macrophages and endothelial cells
2Reliability
If therapeutic agents are delivered systemically, then broad coverage is achieved, but uptake by mononuclear phagocyte system increases
Solution Approach 1:
The invention exploits the fact that activated macrophages at inflamed sites are the primary target for therapy. By designing a liposome with a targeting ligand that specifically binds to receptors on activated macrophages, the potential harmful uptake by the mononuclear phagocyte system is converted into beneficial targeted delivery. The same cell type that would normally clear the liposome non-specifically becomes the precise destination for therapeutic payload delivery
3Duration of action of moving object
If PEG coating is applied to liposomes, then circulation time is improved, but targeting capability may be reduced
Solution Approach 1:
The liposomal composition merges two previously separate functions into a single integrated system: the PEG coating provides extended circulation time by reducing opsonization and phagocytic uptake, while the targeting ligand attached to the liposome surface provides specific binding to inflamed tissues. These two modifications work synergistically rather than antagonistically, allowing the liposome to first evade clearance during circulation and then specifically bind at the target site
Solution Approach 2:
The liposome is constructed as a composite structure combining PEG-coated lipids with targeting ligand-conjugated lipids. This composite approach allows the simultaneous incorporation of both circulation-enhancing (PEG) and targeting (ligand) properties into a single liposomal system, with each component contributing its specific function without compromising the other
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhanced delivery of therapeutic agents to inflamed sites with reduced systemic distribution, improved treatment efficacy for inflammatory diseases, and effective visualization of inflammatory regions through targeted imaging, as demonstrated by increased uptake and reduced competitive inhibition by excess folic acid.
Implementation Method 1
utilizing a folate-targeting ligand to selectively deliver therapeutic and diagnostic agents to inflamed tissues by exploiting the high expression of folate receptors on activated macrophages and endothelial cells
Data Source
AI summary
The invention described herein pertains to folate-receptor targeted agents comprising therapeutic agents useful for the treatment of inflammatory disease, including folate-receptor targeted liposomes (folate-targeted liposomes) containing entrapped therapeutic agents and folate-receptor targeted dendrimers conjugated to therapeutic agents (folate-targeted dendrimer conjugates), useful for the treatment of inflammatory disease, including auto-immune disease, as well as to folate-targeted liposomes containing entrapped imaging agents and dendrimer conjugates conjugated to imaging agents, for use in the diagnosis and monitoring of treatment in such disease.